newsfilter
← Earnings
Earnings Releases·

Cardiff Oncology — Third Quarter 2026 Earnings Summary

  • Total operating expenses for the nine months ended September 30, 2026, decreased 23% to $32.0 million, driving a net loss reduction to $30.4 million ($0.43 per share) from $38.6 million ($0.58 per share) in the prior year period.
  • Cash resources of $33.8 million are projected to fund operations through the end of Q3 2027, following a $10 million registered direct offering in July 2026 that raised approximately $9.1 million in net proceeds.
  • The registrational Phase 3 trial for onvansertib in first-line RAS-mutated mCRC is targeted to begin in Q1 2027, supported by ongoing Phase 2 data showing median progression-free survival not yet reached in the treatment arm versus approximately 11 months in standard-of-care arms.
  • Strategic milestones include the resolution of all outstanding disputes with licensor Nerviano Medical Sciences regarding global onvansertib rights in September 2026 and the appointment of Leila Alland, MD, as interim Chief Medical Officer in October 2026.
Company
CARDIFF ONCOLOGY INC
Sector
Healthcare
Industry
Biotechnology